Where next for the pharma supertankers?

PHARMAS

clock

This year has been earmarked ‘the patent cliff' for pharmaceuticals.

The US Food & Drug Administration (FDA) no longer grants companies 15-year patents for minor improvements on existing drugs. So, as the current generation of blockbuster patents expire, competition opens, profits and margins collapse, causing additional headaches for large R&D-centric firms. So why go overweight pharma? First, the concerns above are priced in. Second, these companies already know they have challenged business models and can do something about it. What you are seeing are companies cutting costs by being less complacent in their R&D, by cutting sales forces and by re-ex...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Investment

Stories of the Week: Bernanke calls on BoE; US inflation drops; abrdn relaunches two fixed income portfolios

Stories of the Week: Bernanke calls on BoE; US inflation drops; abrdn relaunches two fixed income portfolios

BoE; US inflation; abrdn: The biggest stories from the world of investment and asset management this week

Sarka Halas
clock 17 May 2024 • 1 min read
Stories of the Week: BoE holds interest rates; FCA: Name and shame consultation 'valid'; Concord sticks with offer for Hipgnosis

Stories of the Week: BoE holds interest rates; FCA: Name and shame consultation 'valid'; Concord sticks with offer for Hipgnosis

BoE; FCA; Concord: The biggest stories from the world of investment and asset management this week

Sarka Halas
clock 10 May 2024 • 1 min read
Partner Insight: Adding emerging market debt exposure? Look to local bonds.

Partner Insight: Adding emerging market debt exposure? Look to local bonds.

There are five factors that make a strong case for emerging markets in a global fixed income portfolio.

Arif Husain Head of Fixed Income and Chief Investment Officer, Fixed Income, T.Rowe Price
clock 08 May 2024 • 6 min read
Trustpilot